Cargando…

Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways

BACKGROUND: Many chronic metabolic diseases, such as obesity and type 2 diabetes (T2DM), are closely related to a chronic low-grade inflammatory state in tissues. The high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM is related to the role of inflammation in the dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Ying, Yang, Pijian, Li, Zhengming, Luo, Yunchen, Shen, Jing, Li, Ruwen, Zheng, Hua, Liang, Yuzhen, Xia, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896910/ https://www.ncbi.nlm.nih.gov/pubmed/31819375 http://dx.doi.org/10.2147/DDDT.S224688

Ejemplares similares

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
por: Yang, Pijian, et al.
Publicado: (2019)

Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway
por: Li, Zhengming, et al.
Publicado: (2019)

Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway
por: Sun, Yue, et al.
Publicado: (2020)

Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents with obesity: a meta-analysis
por: Sun, Yue, et al.
Publicado: (2019)

Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System
por: Yang, Mengying, et al.
Publicado: (2020)

Prevalence of abnormal glucose homeostasis in Chinese patients with non-transfusion-dependent thalassemia
por: Luo, Yunchen, et al.
Publicado: (2019)

Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
por: Tian, Feng, et al.
Publicado: (2018)

Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease
por: Duan, Yamei, et al.
Publicado: (2022)

Effects of Tea against Alcoholic Fatty Liver Disease by Modulating Gut Microbiota in Chronic Alcohol-Exposed Mice
por: Li, Bangyan, et al.
Publicado: (2021)

Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease
por: Zhang, Zhongyong, et al.
Publicado: (2018)

Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non‐alcoholic fatty liver disease: A randomized trial
por: Feng, Wen‐Huan, et al.
Publicado: (2018)

Association between inflammatory markers and non-alcoholic fatty liver disease in obese children
por: Duan, Yamei, et al.
Publicado: (2022)

Determining whether the effect of liraglutide on non‐alcoholic fatty liver disease depends on reductions in the body mass index
por: Shiomi, Megumi, et al.
Publicado: (2020)

Analysis of N6-Methyladenosine Methylation Modification in Fructose-Induced Non-Alcoholic Fatty Liver Disease
por: Luo, Yunchen, et al.
Publicado: (2021)

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet
por: Zhang, Ningjing, et al.
Publicado: (2020)

Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
por: Wang, Xin, et al.
Publicado: (2011)

Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide
por: Kamm, Dakota R., et al.
Publicado: (2021)

Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway
por: Yu, Peng, et al.
Publicado: (2019)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis
por: Rahman, Khalidur, et al.
Publicado: (2016)

Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
por: Guo, Tingli, et al.
Publicado: (2023)

Barley Sprouts Extract Attenuates Alcoholic Fatty Liver Injury in Mice by Reducing Inflammatory Response
por: Lee, Yun-Hee, et al.
Publicado: (2016)

Protective effects of tea extracts against alcoholic fatty liver disease in mice via modulating cytochrome P450 2E1 expression and ameliorating oxidative damage
por: Li, Bang‐Yan, et al.
Publicado: (2021)

Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis
por: Li, Hang-Yu, et al.
Publicado: (2023)

Preventive Effects of Different Black and Dark Teas on Obesity and Non-Alcoholic Fatty Liver Disease and Modulate Gut Microbiota in High-Fat Diet Fed Mice
por: Li, Bangyan, et al.
Publicado: (2022)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Imatinib reduces non-alcoholic fatty liver disease in obese mice by targeting inflammatory and lipogenic pathways in macrophages and liver
por: AlAsfoor, Shefaa, et al.
Publicado: (2018)

Alleviation of Alcoholic Fatty Liver by Dendrobium officinale Flower Extracts due to Regulation of Gut Microbiota and Short-Chain Fatty Acids in Mice Exposed to Chronic Alcohol
por: Zhang, Jingchi, et al.
Publicado: (2023)

Effects of Different Green Tea Extracts on Chronic Alcohol Induced-Fatty Liver Disease by Ameliorating Oxidative Stress and Inflammation in Mice
por: Li, Bang-Yan, et al.
Publicado: (2021)

Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease
por: Wu, Dongqing, et al.
Publicado: (2021)

Effects of Different Green Teas on Obesity and Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice
por: Zhou, Dan-Dan, et al.
Publicado: (2022)

Status of hepatic DNA methylome predetermines and modulates the severity of non-alcoholic fatty liver injury in mice
por: Tryndyak, Volodymyr P., et al.
Publicado: (2016)

Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease
por: Ying, Xing, et al.
Publicado: (2023)

Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease
por: Luo, Wenjing, et al.
Publicado: (2017)

Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice
por: Kang, Kai, et al.
Publicado: (2021)

Effect of Non-Alcoholic Fatty Liver Disease on Estimated Glomerular Filtration Rate Could Be Dependent on Age
por: Shen, Zhe, et al.
Publicado: (2015)

Liraglutide Is Protective against Brain Injury in Mice with Febrile Seizures by Inhibiting Inflammatory Factors
por: Wang, Xing, et al.
Publicado: (2022)

Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats
por: Shen, Shu-Hua, et al.
Publicado: (2020)

Lactobacillus plantarum ZJUIDS14 alleviates non-alcoholic fatty liver disease in mice in association with modulation in the gut microbiota
por: Cao, Feiwei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rfln1mbrmhak8uuch3ge9finc4